Company intelligence / Profile preview

Artes Medical

Langenfeld, Nordrhein-Westfalen, Germany

Ownership: Private
Employees: ~24
Development stage: Other

Overview

ARTES Biotechnology’s proprietary yeast and VLP technologies have enabled commercially successful production of several vaccines and biopharmaceuticals, with clinical validation in hepatitis B/C, insulin, interferon, and newly added rHSA. Their recombinant VLP technology has been deployed for human and animal health vaccines across client partners globally.

Therapeutic areas: ImmunologyEndocrinologyInfectious DiseasesHematologyOther
Modalities: Recombinant proteinEnzymeVirus-like particle (VLP)-based therapyVaccineBiosimilarAntigenSmall molecule
Industry: Contract Manufacturing Organization

Partnerships

Basic Pharma (Netherlands)Minapharm (Egypt)Bio Farma (Indonesia)Cellumed (South Korea)Richter-Helm BioLogics (Germany)

Beyond the preview

Go deeper on Artes Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Artes Medical.

Explore the full profile